Young-Ho Lee
Algemeen Directeur bij Immunique Co. Ltd.
Actieve functies van Young-Ho Lee
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| Hanyang University | Corporate Officer/Principal | - | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Algemeen Directeur | - | - |
Loopbaan van Young-Ho Lee
Eerdere bekende functies van Young-Ho Lee
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NANOENTEK, INC. | Directeur/Bestuurslid | 24-03-2022 | 08-09-2023 |
| Independent Dir/Board Member | 24-03-2022 | 08-09-2023 |
Opleiding van Young-Ho Lee
| Hanyang University | Doctorate Degree |
Statistieken
Internationaal
| Zuid-Korea | 4 |
Operationeel
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
- Beurs
- Insiders
- Young-Ho Lee
- Ervaring